Andrew Witty

Board

Since February 2021

Age

60 years

Education

Graduated from the University of Nottingham with a degree in Economics.

Tenure

Joined the UNH Board as an independent director in August 2017, later served as CEO of Optum from July 2018 to April 2021 and as President from November 2019 to February 2021 before being appointed as CEO in February 2021.

Also at UnitedHealth Group Inc

Chris Zaetta

EVP, Chief Legal Officer, and Corporate Secretary

Erin McSweeney

EVP, Chief People Officer

John Rex

President and CFO

About

Andrew Witty is a globally experienced leader in the healthcare sector, known for his strategic approach and commitment to innovation in the face of complex industry challenges.

His career began with significant roles in the pharmaceutical industry, where he honed his expertise and built a foundation in global health, transitioning into leadership positions that emphasized collaboration and long‐term value creation.

At UnitedHealth Group, his progression from an independent director in August 2017 to key roles such as CEO of Optum and President, and ultimately to CEO in February 2021, underscores his ability to drive transformational change and manage diverse operational challenges.

His leadership has been marked by addressing critical issues such as cybersecurity challenges and supporting global health initiatives, reflecting a deep commitment to both strategic growth and the broader well-being of global communities.

$UNH Performance Under Andrew Witty

Past Roles

Organization	Role	Date Range	Details
UnitedHealth Group (Optum)	Chief Executive Officer	July 2018 - April 2021	Served as CEO of Optum before becoming UNH CEO
UnitedHealth Group	President	November 2019 - February 2021	Former position at UNH
UnitedHealth Group	Director	August 2017 - March 2018	Served as an independent director
GlaxoSmithKline (GSK)	Chief Executive Officer and Board Member	2008 - April 2017	Held role in a global pharmaceutical company prior to joining UNH

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,500,000	Annual [N/A]	Remained unchanged from 2022
Supplemental Group Term Life Insurance	$2 million face value	Annual benefit [N/A]	Provided by company at its expense
Tax Equalization Payments	$223,532	2023 [N/A]	Covers tax equalization and tax return preparation costs
Long-Term Disability Coverage	60% of base salary (~$900,000)	Contingent upon a qualifying event [N/A]	Coverage provided at company expense; calculated as 60% of $1,500,000

Performance Compensation

Data from FY 2023

Annual Cash Incentive Award

Metric	Details	Source
Revenue Growth	$40.9 billion (13% YoY increase)
Operating Income Growth	$4.2 billion (15% YoY increase)
Operating Cash Flow Growth	$1.8 billion (7% YoY increase)
Target Award	$3,000,000 (200% of base salary)
Maximum Award	$6,000,000 (200% of target)
Actual Award Paid	$1,800,000 (60% of target award)
Payment Type	Cash incentive	[N/A]

Performance Shares

Metric	Details	Source
Performance Measures	Cumulative AEPS and Average ROE
Threshold Shares	22 shares
Target Shares	20,339 shares
Maximum Shares	40,678 shares
Vesting Schedule	100% vesting at the end of the 3-year period (2023-2025)
Grant Date	February 23, 2023
Grant Date Fair Value	$10,000,483
Grant Date Stock Price	$491.69 per share
Actual Shares Awarded	Dependent on performance; not specified

Long-Term Performance Shares

Metric	Details	Source
Performance Measures	Cumulative AEPS and Average ROE
Threshold Shares	22 shares
Target Shares	20,339 shares
Maximum Shares	40,678 shares
Actual Shares Awarded	22,807 shares (127% of target)
Vesting Schedule	100% vesting at the end of the 3-year period (2023-2025)
Grant Date	February 23, 2023
Grant Date Fair Value	$10,000,483
Grant Date Stock Price	$491.69 per share
Additional Notes	Probable outcome estimated at target level